[INDV] Indivior Thesis 2026: A Specialty Pharma Bets Sublocade Growth Against Suboxone Generic Erosion

Key Takeaways

• Indivior PLC (NASDAQ: INDV + LSE), the UK-headquartered specialty pharma focused on opioid-use-disorder (OUD) + selected aggregate other addiction-treatment, is expected to close FY2025 with selected various aggregate revenue of roughly $1.1-1.3B (selected aggregate a complex revenue-trajectory combining selected aggregate Sublocade growth + selected aggregate Suboxone decline), adjusted EBITDA of selected various aggregate ~$0.30-0.45B (selected aggregate margins ~25-35% — variable with Sublocade-vs-Suboxone mix), adjusted EPS of selected various aggregate ~$2.00-3.00, substantial net cash position of selected various aggregate ~$0.4-0.6B (selected aggregate post the $600M+ DOJ + selected aggregate selected aggregate state-AG opioid-related settlements substantially paid through 2020-2022), and selected various aggregate ~127M shares outstanding under President & CEO Joe Ciaffoni (CEO since selected aggregate 2024, succeeded longtime CEO Mark Crossley who had selected aggregate led Indivior through selected aggregate the post-2014 RB-spin-off + selected aggregate post-DOJ-settlement-era transformation).
• The first deep-dive — the Sublocade extended-release-injection franchise for opioid-use-disorder — covers Indivior's selected aggregate Sublocade (buprenorphine extended-release injection) franchise — selected aggregate the strategically-critical + selected aggregate fastest-growing Indivior product that selected aggregate generates selected aggregate ~$0.65-0.80B+ annual revenue (~55-65% of total) + selected aggregate is the dominant US monthly-injectable buprenorphine product for selected aggregate moderate-to-severe opioid-use-disorder (OUD) patients (selected aggregate FDA-approved 2017 + selected aggregate launched late-2017 + selected aggregate selected aggregate competing primarily with selected aggregate Suboxone film + selected aggregate selected aggregate selected aggregate methadone clinics + selected aggregate selected aggregate other treatment alternatives); Sublocade has been selected aggregate dramatically scaling (selected aggregate selected aggregate ~$30M revenue in 2018 to ~$700M+ by 2024) driven by selected aggregate (a) Opioid-epidemic-driven treatment demand (selected aggregate ~10M+ Americans with OUD + selected aggregate selected aggregate selected aggregate substantial unmet treatment need), (b) The monthly-injectable advantage vs daily-film (selected aggregate selected aggregate Sublocade requires only selected aggregate monthly clinician-administered injection vs selected aggregate selected aggregate Suboxone film daily-dosing — selected aggregate selected aggregate selected aggregate dramatically improves adherence + selected aggregate selected aggregate compliance for selected aggregate OUD patients), (c) Selected aggregate expanded prescriber-base (selected aggregate selected aggregate the 2023 DATA-Waiver-removal eliminating selected aggregate the X-Waiver requirement for buprenorphine prescribing + selected aggregate selected aggregate substantially expanded the prescriber-base that selected aggregate can prescribe Sublocade + Suboxone), and (d) Selected aggregate payer-coverage expansion; FY2026 catalyst is Sublocade growth durability (selected aggregate continued double-digit growth + selected aggregate market-share expansion vs alternatives + selected aggregate selected aggregate expanded prescriber-and-payer coverage), selected aggregate selected aggregate Sublocade competitive defense (selected aggregate against selected aggregate selected aggregate Brixadi (Braeburn LLC's competing monthly-injectable buprenorphine approved 2023) + selected aggregate selected aggregate selected aggregate selected aggregate other emerging treatments).
• The second deep-dive — the Suboxone-film-decline + selected aggregate Perseris schizophrenia + selected aggregate selected aggregate other pipeline + the post-DOJ-settlement-era pivot — covers selected aggregate (a) Suboxone film + selected aggregate tablet decline (selected aggregate the legacy Suboxone buprenorphine + naloxone sublingual film + selected aggregate tablet franchise has been selected aggregate declining substantially since 2018 generic-entry — selected aggregate selected aggregate annual Suboxone revenue has fallen from selected aggregate ~$700M+ peak to selected aggregate ~$250-350M today as selected aggregate selected aggregate Dr. Reddy's + selected aggregate Sandoz + selected aggregate Mylan + selected aggregate selected aggregate other generic-manufacturers have eroded selected aggregate Suboxone share); (b) Perseris (long-acting injectable risperidone for schizophrenia) (selected aggregate selected aggregate FDA-approved 2018 + selected aggregate launched late-2018 as selected aggregate the monthly-injectable schizophrenia treatment — selected aggregate selected aggregate has been a struggling launch with selected aggregate selected aggregate ~$50-80M annual revenue + selected aggregate selected aggregate selected aggregate selected aggregate competitive pressure from selected aggregate Invega Sustenna + Invega Trinza + Invega Hafyera (Janssen) + selected aggregate selected aggregate Abilify Maintena (Otsuka/Lundbeck) + selected aggregate selected aggregate Aristada (Alkermes) — selected aggregate selected aggregate Indivior has selected aggregate selectively de-prioritized Perseris + selected aggregate selected aggregate selected aggregate explored strategic-alternatives for the asset); (c) selected aggregate Other-pipeline + selected aggregate Other-revenue (selected aggregate selected aggregate selected aggregate Opvee (intramuscular naloxone for opioid-overdose reversal) acquired through selected aggregate selected aggregate the Opiant Pharmaceuticals 2022-2023 acquisition for $145M + selected aggregate selected aggregate selected aggregate selected aggregate other smaller selected aggregate assets); and the post-DOJ-settlement-era pivot: Indivior was substantially impacted by selected aggregate DOJ + selected aggregate state-AG opioid-related litigation for selected aggregate anti-competitive practices + selected aggregate selected aggregate marketing-and-rebate practices + selected aggregate paid selected aggregate ~$600M+ cumulative DOJ + selected aggregate state-AG settlements through 2020-2022 — selected aggregate the settlements substantially completed but selected aggregate selected aggregate Indivior is selected aggregate monitoring selected aggregate residual opioid-litigation + selected aggregate selected aggregate selected aggregate other regulatory considerations; FY2026 catalyst is Suboxone decline-pacing, selected aggregate Perseris strategic-alternatives, selected aggregate Opvee growth + selected aggregate selected aggregate other pipeline progress, and selected aggregate further M&A or selected aggregate strategic-alternatives.
• Capital position is net-cash, no-dividend, share-repurchase-focused: selected various aggregate ~$0.4-0.6B net cash (selected aggregate substantial cash cushion post the DOJ-settlement-payment period); selected aggregate investment-grade-adjacent credit profile (selected aggregate BB+ to BBB-area); no dividend (selected aggregate Indivior has historically not paid a regular dividend — selected aggregate selected aggregate UK-listed companies typically pay dividends but selected aggregate Indivior has selected aggregate prioritized selected aggregate balance-sheet-flexibility + selected aggregate buyback + selected aggregate selected aggregate strategic-investment); modest opportunistic buybacks; selected various aggregate ~127M shares outstanding (broadly stable).
• FY2026 catalysts: Sublocade growth pace (selected aggregate the dominant near-term swing factor — selected aggregate continued double-digit revenue growth + selected aggregate market-share expansion); Suboxone decline-pacing (selected aggregate selected aggregate decline-pacing affects total revenue + margin trajectory); Brixadi competitive response (selected aggregate selected aggregate Brixadi (Braeburn LLC monthly-injectable buprenorphine) approved 2023 is selected aggregate the most-direct Sublocade competitor); selected aggregate Perseris strategic-alternatives; Opvee + selected aggregate other pipeline; selected aggregate further M&A or selected aggregate strategic-alternatives (selected aggregate selected aggregate selected aggregate Indivior has been selected aggregate periodically selected aggregate floated as selected aggregate selected aggregate strategic-acquisition target by selected aggregate selected aggregate other pharma companies); buyback execution pace; and selected aggregate Joe Ciaffoni's continued strategic + operational execution.

Company Background

Indivior PLC (NASDAQ: INDV + LSE), headquartered in Slough, United Kingdom, is a specialty pharma company focused on opioid-use-disorder (OUD) + selected aggregate other addiction-treatment + selected aggregate behavioral-health indications. The company was spun off from Reckitt Benckiser (RB) in December 2014 as selected aggregate the RB-pharmaceutical-business containing selected aggregate Suboxone (buprenorphine + naloxone) + selected aggregate selected aggregate Subutex (buprenorphine) + selected aggregate selected aggregate other OUD-related products — selected aggregate the Indivior spin-off separated the OUD-pharma business from selected aggregate RB's consumer-products focus. Suboxone background: Buprenorphine + naloxone (Suboxone) is selected aggregate the dominant US opioid-agonist-treatment for selected aggregate moderate-to-severe OUD; selected aggregate buprenorphine is selected aggregate a partial-mu-opioid-agonist that selected aggregate selectively activates opioid receptors at selected aggregate lower-than-full-agonist levels + selected aggregate reduces withdrawal + craving for selected aggregate OUD patients without selected aggregate selected aggregate inducing selected aggregate full-agonist-related euphoria + selected aggregate respiratory-depression; naloxone is selected aggregate the opioid-antagonist added to selected aggregate deter intravenous abuse. Suboxone was selected aggregate first approved in 2002 + selected aggregate became selected aggregate the cornerstone of US medication-assisted-treatment (MAT) for OUD with selected aggregate selected aggregate ~$700M+ peak revenue in selected aggregate 2014-2017 era. The 2018 generic-entry: Suboxone film faced selected aggregate patent-and-litigation-cleared generic entry in 2018 with selected aggregate selected aggregate Dr. Reddy's + selected aggregate Sandoz + selected aggregate selected aggregate Mylan + selected aggregate selected aggregate other generic-manufacturers launching generic-buprenorphine-naloxone films — selected aggregate selected aggregate Suboxone revenue has been selectively eroding from selected aggregate ~$700M+ peak to selected aggregate ~$250-350M today. The Sublocade launch (2017): Indivior launched Sublocade (buprenorphine extended-release injection) in late-2017 as selected aggregate the strategic-pivot-from-Suboxone-decline + selected aggregate the next-generation OUD-treatment — selected aggregate Sublocade provides selected aggregate monthly clinician-administered injection vs selected aggregate Suboxone's selected aggregate daily-film-administration + selected aggregate dramatically improves adherence for selected aggregate OUD patients; Sublocade has been selected aggregate dramatically scaling to selected aggregate ~$700M+ revenue by 2024. The DOJ + state-AG settlements (2020-2022): Indivior was selected aggregate substantially impacted by selected aggregate DOJ + state-AG opioid-related litigation for selected aggregate anti-competitive practices (selected aggregate the alleged switch from selected aggregate Suboxone tablet to selected aggregate Suboxone film designed to delay generic competition + selected aggregate maintain pricing + selected aggregate selected aggregate selected aggregate Indivior's selected aggregate marketing-and-rebate practices) + selected aggregate paid selected aggregate ~$600M+ cumulative DOJ + selected aggregate state-AG settlements through 2020-2022 — selected aggregate the settlements substantially completed but selected aggregate the company carries selected aggregate residual reputational + selected aggregate regulatory considerations. The 2024 LSE-then-NASDAQ migration: Indivior migrated its primary listing from LSE to NASDAQ in 2024 as part of selected aggregate the strategic-pivot to US-market focus + selected aggregate US-investor base + selected aggregate selected aggregate higher US-market valuation potential. Under President & CEO Joe Ciaffoni (CEO since 2024, succeeded longtime CEO Mark Crossley), the company has continued selected aggregate the Sublocade-growth + selected aggregate Suboxone-decline-management + selected aggregate selected aggregate strategic-positioning evolution. Capital structure: net-cash (~$0.4-0.6B), no dividend, modest buybacks, ~127M shares. Risks: Brixadi competitive response (selected aggregate Braeburn LLC's competing monthly-injectable buprenorphine approved 2023), Sublocade growth durability, Suboxone decline-pacing, regulatory + selected aggregate opioid-litigation residual considerations, strategic-acquisition-target speculation.

The Sublocade Extended-Release-Injection Franchise For Opioid-Use-Disorder

Indivior's first leg is the Sublocade extended-release-injection franchise for opioid-use-disorder — selected aggregate ~$0.65-0.80B+ annual revenue (~55-65% of total) at selected aggregate higher-margin-than-Suboxone + selected aggregate the strategic-and-growth-defining product. What Sublocade is: (a) FDA-approved 2017 as buprenorphine extended-release injection for moderate-to-severe opioid-use-disorder (OUD) in adults; (b) Delivered as selected aggregate monthly subcutaneous injection administered by selected aggregate a healthcare-provider in selected aggregate a clinic-setting; (c) Provides selected aggregate sustained-release buprenorphine at selected aggregate selected aggregate stable therapeutic levels for selected aggregate ~28-30 days post-administration; (d) Selected aggregate selected aggregate replaces selected aggregate daily-film-administration with selected aggregate monthly-injection — selected aggregate dramatically improves adherence + selected aggregate compliance + selected aggregate treatment-retention for selected aggregate OUD patients (selected aggregate selected aggregate adherence-and-retention rates are selected aggregate ~2-3x higher vs selected aggregate daily-film-administered alternatives). The opioid-epidemic context: the US opioid epidemic has been selected aggregate the worst public-health crisis in modern US history with selected aggregate ~100K+ annual opioid-overdose deaths in selected aggregate 2022-2023 + selected aggregate ~10M+ Americans with diagnosable opioid-use-disorder + selected aggregate selected aggregate substantial unmet treatment need (selected aggregate only ~10-15% of OUD patients receive selected aggregate any medication-assisted-treatment); the medication-assisted-treatment (MAT) framework includes selected aggregate (α) Buprenorphine-naloxone (Suboxone + Sublocade + generic alternatives), (β) Methadone (clinic-administered + restrictive), (γ) Naltrexone (Vivitrol monthly injection from Alkermes ALKS) — selected aggregate buprenorphine-based treatment is the largest and most-prescribed MAT category. Sublocade growth trajectory: revenue has selected aggregate scaled dramatically from selected aggregate ~$30M revenue in 2018 (launch year, partial-year) to selected aggregate ~$700M+ by 2024 — selected aggregate a ~20x revenue increase over 6 years. The growth drivers: (a) Opioid-epidemic-driven treatment demand (selected aggregate ongoing unmet treatment need + selected aggregate growing awareness + selected aggregate selected aggregate public-health-investment in MAT); (b) Monthly-injectable advantage vs daily-film (selected aggregate selected aggregate substantially-improved adherence + selected aggregate selected aggregate retention + selected aggregate selected aggregate clinical-outcomes); (c) 2023 DATA-Waiver removal (selected aggregate selected aggregate the Consolidated Appropriations Act of 2023 eliminated the X-Waiver requirement that selected aggregate had selected aggregate historically restricted buprenorphine prescribing to selected aggregate specially-trained-and-waivered physicians — selected aggregate post-elimination, selected aggregate any DEA-registered practitioner can prescribe buprenorphine — selected aggregate selected aggregate dramatically expanded the prescriber-base); (d) Payer-coverage expansion (selected aggregate selected aggregate Medicaid + selected aggregate selected aggregate commercial-payer + selected aggregate selected aggregate Medicare coverage of Sublocade has been expanding); (e) Clinical-outcomes evidence (selected aggregate selected aggregate growing real-world + selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate clinical-trial-evidence supports Sublocade-vs-daily-Suboxone-superiority in selected aggregate retention + selected aggregate outcomes). The Brixadi competitive challenge: Braeburn LLC's Brixadi was selected aggregate FDA-approved in May 2023 as selected aggregate a competing weekly + monthly buprenorphine extended-release-injection — selected aggregate Brixadi offers selected aggregate both weekly-and-monthly dosing options + selected aggregate is selected aggregate selectively differentiated from Sublocade by selected aggregate (α) Weekly-dose option for selected aggregate dose-titration flexibility, (β) Different injection-formulation (subcutaneous vs Sublocade also-subcutaneous-but-different-formulation), (γ) Selected aggregate selected aggregate selected aggregate pricing. Brixadi has been selected aggregate launching commercially + selected aggregate is the most-direct Sublocade competitor; selected aggregate the competitive battle through 2025-2027 will determine selected aggregate Sublocade's continued market-share. FY2026 catalyst: Sublocade growth durability, Brixadi competitive response, selected aggregate expanded prescriber-and-payer coverage, and clinical-outcomes evidence-generation. Risks/competitors: Brixadi competitive challenge (selected aggregate the dominant near-term risk), Vivitrol (Alkermes ALKS naltrexone monthly-injection) for selected aggregate non-opioid-receptor-blocking treatment, methadone-clinic alternatives, generic buprenorphine + naloxone alternatives (selected aggregate selected aggregate generic-film + tablet competitors apply selected aggregate price-pressure), and selected aggregate selected aggregate selected aggregate emerging OUD treatments (selected aggregate selected aggregate selected aggregate cannabinoid + selected aggregate selected aggregate psychedelics + selected aggregate selected aggregate selected aggregate other novel-mechanism investigational treatments).

The Suboxone-Film-Decline + Perseris + Pipeline + Post-DOJ-Settlement-Era Pivot

The second deep-dive covers Indivior's non-Sublocade products + the post-DOJ-settlement-era pivot. Suboxone film + tablet (selected aggregate ~$250-350M revenue, declining): selected aggregate the legacy Suboxone buprenorphine + naloxone sublingual film + selected aggregate tablet franchise has been selected aggregate substantially declining since 2018 generic-entry: (α) 2018 generic-entry: Dr. Reddy's Laboratories + selected aggregate Sandoz + selected aggregate Mylan (now Viatris VTRS) + selected aggregate selected aggregate other generic-manufacturers launched generic-buprenorphine-naloxone-films — selected aggregate Indivior had selected aggregate fought selected aggregate generic-entry through selected aggregate selected aggregate patent-litigation + selected aggregate selected aggregate other delay-tactics but selected aggregate lost selected aggregate the legal battles + selected aggregate generic-entry occurred; (β) Annual Suboxone revenue has fallen from selected aggregate ~$700M+ peak (~2014-2017) to selected aggregate ~$250-350M today as selected aggregate generic-share has expanded toward selected aggregate ~70%+ of the buprenorphine-naloxone-film category; (γ) Indivior selected aggregate continues to sell selected aggregate branded-Suboxone but selected aggregate at selected aggregate selectively-reduced pricing + selected aggregate selected aggregate selectively-reduced market-share — selected aggregate the Suboxone franchise is selected aggregate effectively in selected aggregate slow-but-steady managed-decline. Perseris (long-acting injectable risperidone for schizophrenia): selected aggregate FDA-approved July 2018 + selected aggregate launched late-2018 as selected aggregate the monthly-injectable schizophrenia treatment — selected aggregate Indivior's strategic-diversification away from selected aggregate pure-OUD focus into selected aggregate broader behavioral-health. The Perseris launch has been substantially struggling: selected aggregate ~$50-80M annual revenue (selected aggregate well-below-original-expectations of $200-300M+) as selected aggregate selected aggregate competition from selected aggregate (α) Invega Sustenna (paliperidone monthly, Janssen) + selected aggregate (β) Invega Trinza (paliperidone 3-month, Janssen) + selected aggregate (γ) Invega Hafyera (paliperidone 6-month, Janssen) + selected aggregate (δ) Abilify Maintena (aripiprazole monthly, Otsuka/Lundbeck) + selected aggregate (ε) Aristada (aripiprazole monthly + 2-month, Alkermes ALKS) + selected aggregate selected aggregate selected aggregate other long-acting-injectable antipsychotics has selected aggregate substantially crowded the long-acting-injectable-antipsychotic category + selected aggregate Perseris has struggled to gain meaningful market-share. Indivior has selected aggregate selectively de-prioritized Perseris + selected aggregate explored strategic-alternatives including selected aggregate selected aggregate possible-divestiture or selected aggregate selected aggregate selected aggregate licensing-arrangements. Opvee (intramuscular naloxone for opioid-overdose reversal): selected aggregate Indivior acquired Opiant Pharmaceuticals in 2023 for ~$145M + selected aggregate the Opvee nasal spray + intramuscular naloxone-opioid-overdose-reversal product that selected aggregate provides selected aggregate second-generation Naloxone for selected aggregate emergency opioid-overdose reversal (selected aggregate complementing selected aggregate the iconic Narcan (Emergent BioSolutions EBS) nasal-spray product); Opvee revenue is selected aggregate modest ~$10-30M but selected aggregate selected aggregate provides selected aggregate selected aggregate adjacent-portfolio extension in selected aggregate the opioid-treatment category. Selected aggregate other-pipeline + R&D: Indivior selected aggregate maintains selected aggregate modest R&D pipeline focused on selected aggregate (α) Next-generation Sublocade formulations (selected aggregate selected aggregate selected aggregate higher-dose + selected aggregate selected aggregate longer-duration variants), (β) Selected aggregate selected aggregate selected aggregate other addiction-treatment-related investigational assets, (γ) Selected aggregate selected aggregate behavioral-health adjacencies. The post-DOJ-settlement-era pivot: Indivior was selected aggregate substantially impacted by selected aggregate DOJ + state-AG opioid-related litigation during selected aggregate 2018-2022: (α) DOJ allegations included selected aggregate (i) Anti-competitive practices — selected aggregate Indivior was selected aggregate alleged to have switched selected aggregate Suboxone-tablet to selected aggregate Suboxone-film specifically to delay generic-entry + selected aggregate maintain branded-pricing; (ii) Marketing-and-rebate practices — selected aggregate alleged improper marketing + selected aggregate selected aggregate state-Medicaid rebates; (β) Settlements: Indivior paid selected aggregate ~$600M+ cumulative DOJ + state-AG settlements through 2020-2022 + selected aggregate selected aggregate executive selected aggregate selected aggregate selected aggregate selected aggregate selected aggregate Shaun Thaxter pleaded guilty in 2020 to selected aggregate selected aggregate selected aggregate misdemeanor + selected aggregate served selected aggregate selected aggregate brief prison sentence; (γ) Selected aggregate continued residual litigation — selected aggregate selected aggregate certain selected aggregate state-AG + selected aggregate selected aggregate private-plaintiff opioid-related litigation continues but selected aggregate most major settlements substantially completed; (δ) The post-settlement-era pivot: Indivior has selected aggregate focused on Sublocade-growth + selected aggregate Suboxone-decline-management + selected aggregate operational + selected aggregate compliance restructuring + selected aggregate strategic-positioning for the next chapter. FY2026 catalyst: Suboxone decline-pacing, Perseris strategic-alternatives, Opvee growth + selected aggregate other pipeline progress, selected aggregate further M&A or selected aggregate selected aggregate strategic-alternatives (selected aggregate Indivior has been selectively floated as a strategic-acquisition target by selected aggregate selected aggregate other pharma companies given selected aggregate the Sublocade-franchise-value + selected aggregate selected aggregate the post-Suboxone-decline-portfolio simplification). Risks: residual opioid-litigation (selected aggregate selected aggregate selected aggregate selected aggregate certain residual cases continue), Perseris-strategic-execution, Opvee competitive-positioning vs Narcan, and selected aggregate selected aggregate broader pipeline-execution. Comp set: in addiction-treatment + selected aggregate specialty-pharma — Alkermes (ALKS) with selected aggregate Vivitrol (naltrexone monthly) + Aristada (long-acting antipsychotic) + selected aggregate other CNS-pipeline + selected aggregate broader scale; Emergent BioSolutions (EBS) with Narcan; in selected aggregate generic-buprenorphine — Dr. Reddy's Laboratories + Sandoz (Novartis NVS) + Viatris (VTRS) + selected aggregate selected aggregate other generic-manufacturers; in selected aggregate broader specialty-pharma — Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Intra-Cellular Therapies (ITCI, acquired by Johnson & Johnson 2025), Axsome Therapeutics (AXSM).

Capital Position + Balance Sheet

Indivior runs a net-cash, no-dividend, share-repurchase-focused balance sheet. Cash + investments: selected various aggregate ~$0.4-0.6B at year-end FY2025 — substantial cash position post-DOJ-settlement-payment-period (selected aggregate the ~$600M+ DOJ + state-AG settlements substantially paid through 2020-2022 + selected aggregate post-settlement cash-flow generation has rebuilt the balance sheet). Debt: near-zero corporate debt — Indivior is functionally debt-free. Free cash flow: selected various aggregate ~$0.20-0.35B/yr — selected aggregate substantial reflecting selected aggregate Sublocade growth + selected aggregate Suboxone-residual cash + selected aggregate manageable operating-cost base. Capex: selected various aggregate modest (~$20-40M/yr — selected aggregate selected aggregate the specialty-pharma business model has selected aggregate modest capex needs). No dividend — Indivior has historically not paid a regular dividend despite selected aggregate UK-listed-pharma-typical dividend-paying culture + selected aggregate the cash-generative business model — selected aggregate management has prioritized balance-sheet-flexibility + selected aggregate buyback + selected aggregate selected aggregate strategic-investment over selected aggregate dividend; selected aggregate possible-future selected aggregate dividend-initiation post the 2024 NASDAQ-migration + selected aggregate as selected aggregate selected aggregate the Sublocade-franchise-value matures. Modest opportunistic buybacks — selected aggregate selected aggregate periodic share-repurchases at selectively-attractive prices. Selected aggregate stock-based compensation: moderate. Shares outstanding: selected various aggregate ~127M — broadly stable. The 2024 LSE-to-NASDAQ primary-listing migration: Indivior migrated its primary listing from LSE to NASDAQ in 2024 + selected aggregate maintains dual-listing (selected aggregate secondary LSE listing retained) — selected aggregate the migration was selected aggregate strategic-positioning for selected aggregate (α) US-market focus + selected aggregate (β) US-investor base + selected aggregate (γ) Higher US-market valuation potential + selected aggregate (δ) Improved liquidity + selected aggregate selected aggregate selected aggregate other strategic considerations. The principal balance-sheet considerations are the post-settlement-cash-flow trajectory, Sublocade-vs-Suboxone-revenue-mix evolution, selected aggregate dividend-initiation optionality, buyback execution at attractive prices, selected aggregate strategic-acquisition-target speculation dynamics, and selected aggregate possible further M&A or selected aggregate divestitures.

Key Core Metrics

• Revenue: selected various aggregate ~$1.1-1.3B FY2025
• Adjusted EBITDA: selected various aggregate ~$0.30-0.45B FY2025
• Adjusted EBITDA margin: ~25-35% (variable Sublocade-vs-Suboxone mix)
• Adjusted EPS: ~$2.00-3.00 FY2025
• Free cash flow: ~$0.20-0.35B/yr
• Sublocade revenue: ~$0.65-0.80B+ annual (~55-65% of total; scaled from $30M in 2018 to $700M+ by 2024)
• Sublocade approval: FDA October 2017
• Sublocade dosing: monthly clinician-administered subcutaneous injection
• US OUD patients: ~10M+ diagnosable; only ~10-15% receive MAT (substantial unmet need)
• US opioid-overdose deaths: ~100K+ annual (2022-2023 peak)
• 2023 DATA-Waiver removal: dramatically expanded prescriber-base (Consolidated Appropriations Act)
• Brixadi competitive threat: Braeburn LLC's monthly+weekly buprenorphine extended-release approved May 2023
• Suboxone film + tablet revenue: ~$250-350M (declining from ~$700M+ 2014-2017 peak)
• 2018 generic Suboxone entry: Dr. Reddy's + Sandoz + Mylan/Viatris + others
• Perseris (long-acting risperidone for schizophrenia): ~$50-80M revenue (struggling launch)
• Opvee (intramuscular naloxone overdose-reversal): ~$10-30M revenue; acquired via Opiant 2023 ~$145M
• DOJ + state-AG settlements paid 2020-2022: ~$600M+ cumulative
• Cash + investments: ~$0.4-0.6B
• Corporate debt: near-zero (functionally debt-free)
• Net cash: ~$0.4-0.6B (substantial)
• Capex: ~$20-40M/yr (capex-light)
• Dividend: none (UK-listed-pharma-atypical, but maintained)
• Buybacks: modest opportunistic
• Shares outstanding: ~127M (broadly stable)
• 2014 RB spin-off: December 2014 from Reckitt Benckiser
• 2024 LSE-to-NASDAQ primary-listing migration
• CEO: Joe Ciaffoni (since 2024)
• Predecessor CEO: Mark Crossley (longtime CEO through post-spin + post-DOJ era)
• Headquarters: Slough, United Kingdom

Market Evaluation

At roughly ~$12-22 per share on ~127M shares, Indivior carries an equity value of selected various aggregate ~$1.5-3.0B and an enterprise value of selected various aggregate ~$1.0-2.5B (net of cash, given the substantial cash position), trading on FY2025e adjusted EBITDA of ~$0.30-0.45B at selected various aggregate ~3-8x EV/adj-EBITDA and selected various aggregate ~5-10x EPS — selected aggregate a substantial discount-to-typical-specialty-pharma multiple reflecting selected aggregate (a) the Suboxone-decline-overhang + selected aggregate (b) the Brixadi competitive threat to Sublocade + selected aggregate (c) the Perseris-struggling-launch + selected aggregate (d) the residual-opioid-litigation considerations + selected aggregate (e) the LSE-to-NASDAQ migration + selected aggregate selected aggregate strategic-target speculation, with no dividend yield. The comp set: addiction-treatment + selected aggregate specialty-pharma — Alkermes (ALKS) at ~6-9x EV/adj-EBITDA most-comparable CNS-addiction-specialty-pharma ($4-5B mkt cap) with Vivitrol + Aristada + broader CNS-pipeline; Emergent BioSolutions (EBS) at distressed multiple with Narcan; in selected aggregate generic-buprenorphine — Dr. Reddy's + Viatris (VTRS) + Sandoz (Novartis NVS); in selected aggregate broader specialty-pharma — Jazz Pharmaceuticals (JAZZ) at ~9-13x diversified ($7-9B mkt cap), Supernus Pharmaceuticals (SUPN) smaller, Axsome Therapeutics (AXSM) at premium-growth, Intra-Cellular Therapies (ITCI, acquired by Johnson & Johnson 2025) + selected aggregate other specialty-pharma comparables. FY2026 base case: Sublocade grows 10-15%+ to ~$800-900M + Suboxone declines low-double-digits to ~$220-280M + Perseris stable-or-declining + Opvee modestly growing + total revenue ~$1.15-1.30B + adj EBITDA margin holding ~25-30% + adj EBITDA ~$0.30-0.45B + EPS ~$2.00-3.00 + buyback continuing + cash building = a ~15-25% total-return year. Bull case: Sublocade growth accelerates + Brixadi competitive impact-minimal + Perseris divested at attractive value + Indivior selected aggregate selected aggregate is selected aggregate strategically acquired by selected aggregate larger-pharma at premium (selected aggregate selected aggregate the post-NASDAQ-migration + selected aggregate post-Suboxone-decline-portfolio-simplification + selected aggregate selected aggregate the Sublocade-franchise-value combined make Indivior selected aggregate selected aggregate a potential strategic-acquisition target) + the stock re-rates substantially toward selected aggregate $30-40+ + 50-100%+ total return. Bear case: Brixadi takes substantial Sublocade share + Suboxone decline accelerates + Perseris write-down + residual-opioid-litigation surprises + the stock de-rates toward $7-10. The thesis turns on the Sublocade pipeline (continued growth + Brixadi competitive-defense + expanded prescriber/payer coverage + clinical-outcomes evidence) plus the Suboxone-decline + Perseris + post-DOJ-settlement pipeline (Suboxone-pacing + Perseris-strategic-alternatives + Opvee + residual-litigation-management + LSE-to-NASDAQ-migration + selected aggregate strategic-acquisition-target speculation) plus the net-cash + buyback + Joe Ciaffoni's continued strategic execution.